Avanir Targets Watson In Suit Over Nuedexta Patents

Law360, New York (March 06, 2012, 12:49 PM ET) -- Avanir Pharmaceuticals Inc. sued drugmaker Watson Pharmaceuticals Inc. in Delaware on Friday in an effort to block plans to market a generic version of so-called involuntary emotion drug Nuedexta, the latest in a campaign of patent suits over the drug.

Avanir claims that New Jersey-based Watson's planned generic version of the drug — which is sold in capsule form and used to treat involuntary laughing and crying disorders in patients with underlying brain conditions — infringed two of its patents.

The California-based company contends it would...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required